| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -23.5 | -34.4 |
| EPS (diluted, $ a share) | $-0.11 | $-0.40 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: IPSC. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Century Therapeutics, Inc.: key numbers
- Share price
- $1.37Close, Nov 17
- Market cap
- $249M
- Shares outstanding
- 181.6MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Biological Products, (No Diagnostic Substances)SIC 2836
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Century Therapeutics, Inc.
All →Century Therapeutics Financial Results
Century Therapeutics reported third quarter 2026 financial results and provided updates on its iPSC-derived cell therapy pipeline. The company remains on track for an IND submission for CNTY-813 in Q4 2026 and expects its CD19-targeted CAR-iT cell therapy, CNTY-308, to enter the clinic by the end of 2026.
“We remain focused on disciplined execution as we rapidly advance our two potentially transformational programs, including CNTY-813, which has the potential to be a functional cure for type 1 diabetes, toward the clinic over the coming months.”
Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics
“With general alignment reached with the FDA for both programs, we remain on track this year for clinical entry of CNTY-308 and IND submission of CNTY-813, positioning us for an important transition to clinical execution in 2027.”
Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics
Century Therapeutics Clinical Trial Data
Century Therapeutics presented updated nonclinical data for CNTY-813, its iPSC-derived islet replacement therapy for type 1 diabetes, at the EASD 2026 meeting. The data demonstrated sustained glycemic control in diabetic mouse models for over eleven months and confirmed manufacturing consistency across five clinical-scale batches. The company remains on track to submit an IND for CNTY-813 in Q4 2026, with initial clinical data expected in the second half of 2027.
- Counterparty
- European Association for the Study of Diabetes (EASD)